lunes, 4 de abril de 2022

Addition of alirocumab to high-intensity statin treatment reduces key measures of plaque vulnerability

Addition of alirocumab to high-intensity statin treatment reduces key measures of plaque vulnerability
Publicado por en

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)